Guidance for the selection of instruments for measurement of negative symptoms is rapidly evolving. As there are continuing advances in the description of negative symptoms, new instruments are under development, and new data on the performance of instruments emerge from clinical trials.
The 2005 NIMH-MATRICS consensus statement on negative symptoms recommended the use of the Schedule for Assessment of Negative Symptoms (SANS) or Positive and Negative Syndrome Scale (PANSS) but noted weaknesses in both scales. The statement recommended that a workgroup develop and test a new instrument for clinical trials that would address all the currently recognized domains of negative symptom functioning, distinguish appetitive and consummatory aspects of anhedonia and assess a subject's desire for relationships (Kirkpatrick et al., 2006) .
In 2009, representatives of academia, the pharmaceutical industry and the US Food and Drug Administration met in a workshop format under the auspices of the International Society for Clinical Trials Methodology (ISCTM) to update the 2005 recommendations . The consensus was that the Negative Symptom Assessment Scale (NSA-16) along with the SANS and subscales of the PANSS were reliable and valid measures of negative symptoms for clinical trials. The workshop expressed preference for the PANSS negative factors derived from factor analyses over the original PANSS negative subscale.
Although the SANS, PANSS negative factors and NSA-16 perform adequately psychometrically, the scales differentiate in important ways that may impact their fit to clinical trials (Tables 1 and 2 ). Variations among the scales in coverage of the five negative symptom domains identified in the 2005 NIMH-MATRICS consensus statement are shown in Table 1 . The domains represent areas of normal functioning in expression, motivation and pleasure that are impaired in schizophrenia. The evaluation of each domain is important because it is unknown whether their underlying pharmacologies are the same or different and therefore whether they might respond to treatment in different manners (Kirkpatrick et al., 2006) . Only the SANS includes all 5 recommended domain items. However, the SANS also addresses attention, a domain considered to be outside of negative symptoms, and mingles the assessment of anhedonia and asociality. The original PANSS negative symptom subscale contains two items, "stereotyped thinking" and "difficulty in abstract thinking," which are outside the currently recommended negative symptom domains. The PANSS Marder negative factor does not include these items. Neither the NSA-16 nor the PANSS Marder negative factor directly addresses the negative symptom domain, anhedonia. Other PANSS negative factor solutions exist as well (for a review, see Levine and Rabinowitz, 2007) .
The 2009 ISCTM workgroup recommended the use of a global negative symptoms measure in addition to a negative symptom rating scale. The SANS, PANSS and NSA-16 differ in this respect as well. Only the NSA-16 provides a distinct item rating a global measure of negative symptoms. The SANS items assess global scores separately for each domain (Andreasen, 1984 ). An overall summary or composite score for the SANS may also be calculated but is not part of the scale proper. The PANSS Marder negative factor does not include a global items measure. The Clinical Global Impression Schizophrenia Scale (Negative subscale) (Haro et al., 2003) is sometimes used in industry trials as a global measure of negative symptoms to accompany scales that do not incorporate global scores of their own.
The PANSS differs from the SANS and NSA-16 in that informant roles are explicitly described for many items and are the sole basis of rating for 2 of the negative factor items. (Kay et al., 2006) . The NSA-16 instruction manual encourages awareness of informant information and resolution of any conflicts with information provided by the patient (Alphs, 2006) . The Comprehensive Assessment of Symptoms and History (CASH), which incorporates the SANS, recommends the use of informant information when needed, and corroborative history from family members has been shown to improve assessment of negative symptoms by the SANS (Ho et al., 2004) . However, only the PANSS explicitly requires informant information for completion.
Suggested interview questions and prompts are built into the SANS and the instruction manual of the NSA-16. Two extensive clinician-administered structured instruments for interviewing the patient (SCI-PANSS) and informant (IQ-PANSS), respectively, are available for the PANSS.
A survey of 39 US raters participating in a negative symptoms trial found no difference in perceptions of clarity of anchor points among the SANS, PANSS and NSA-16. However, the NSA-16 was viewed as the most effective measure of negative symptoms and the PANSS as the least (F(2,82) = 3.53, p b 0.05) (Daniel et al., 2011b) . In training contexts for international clinical trials, it appears possible to obtain relatively high levels of agreement among investigators in rating negative symptoms with the NSA-16, the PANSS negative subscale and the PANSS Marder negative factor (Daniel et al., 2011a) . Adequate data to compare sensitivity to change among the PANSS negative subscale, PANSS Marder negative factor, NSA-16 and SANS in predominant, persistent negative symptom double-blind, placebo-controlled international clinical trial contexts are not yet available. However, potentially informative trials are in progress.
New instruments
The 2005 NIMH-MATRICS consensus statement on negative symptoms recommended the development and testing of a new instrument for clinical trials that would address the five currently recognized domains of negative symptom functioning (blunted affect, alogia, asociality, anhedonia and avolition), distinguish appetitive and consummatory aspects of anhedonia and assess a subject's desire for relationships (Kirkpatrick et al., 2006) . In the interim, two separate new negative symptom scales, the Brief Negative Symptom Scale (BNSS) and the Clinical Assessment Interview for Negative Symptoms (CAINS) (Forbes, Blanchard et al., 2010; Kirkpatrick et al., 2011, respectively) , have been developed. They are contrasted with each other and the PANSS, SANS and NSA-16 in Table 2 . The BNSS and CAINS each address all 5 negative symptom domains and thus far have demonstrated mostly promising inter-rater and test-retest reliability, convergent and divergent validity and functional correlations (Forbes, Blanchard et al., 2010; Horan et al., 2011; Kirkpatrick et al., 2011; Strauss et al., 2012a; Kring et al., 2013) . Clinical trials experience and assessment of sensitivity to change has not yet been reported. Both scales are expected to undergo additional field testing, refinement and psychometric characterization and are potentially subject to further revision.
Consistent with the 2005 NIMH-MATRICS recommendations and unlike the PANSS, SANS and NSA-16, the BNSS and CAINS differentiate experience of pleasure during the rating period vs. the expectation of pleasure in the future. Unlike the blunted affect item of the PANSS, the BNSS and CAINS use separate items to measure facial expression, vocal expression and expressive gestures. Neither scale includes a global assessment.
The BNSS has 13 items ( Table 3) . The principal component factor analysis with maximum likelihood rotation resulted in two factors: (Strauss et al., 2012b) . The BNSS includes a lack of normal distress item, which had moderate loading on the emotional expressivity factor. For asociality and avolition, the BNSS questions address behavior separately from internal experience. The authors indicate the interview can be completed in 15 min. (Strauss et al., 2012a) .
The CAINS has 13 items divided into a 9-item motivation and pleasure subscale (MAP) and a 4-item expression subscale (EXP) ( Table 4 ). Similar to the BNSS, a two-factor solution broadly differentiated items based on reports of motivation, emotion or closeness from expression items based on observations of behavior (Kring et al., 2012) . Motivation items address both behavior and internal experience. The authors have made training manuals and videos available online at http://www.med.upenn.edu/bbl/downloads/ CAINSVideos.shtml.
Given the relatively early stage of development of the CAINS and BNSS, it is likely that in clinical trials contexts they will be used in conjunction with the PANSS, SANS or NSA-16 until their properties are better defined. Data comparing the psychometric performance of the BNSS and CAINS in the same population are not yet available.
Summary
The SANS, PANSS negative factor and NSA-16 are considered to be reliable and valid measures for negative symptom trials but differ with respect to their domain coverage, use of informants, integration of global scores, administration time and comprehensiveness of their structured interviews. In response to the 2005 NIMH-MATRICS consensus statement, work groups are field testing and refining the CAINS and BNSS, two new measures that address the five currently recognized domains of negative symptoms, differentiate appetitive from consummatory aspects of anhedonia and address desire for social relationships. Thus far, both have exhibited promising psychometric properties. Future clinical trial experience in negative symptom populations will provide data on the relative sensitivity to change and global suitability of the BNSS and CAINS vs. each other and the earlier generation scales. 
